WINNIPEG, MB / ACCESS Newswire / August 20, 2025 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended June 30, 2025. Quarter Ended June 30, 2025 Highlights: Recorded total net revenue of $6.7 million during the quarter ended June 30, 2025 compared to $5.2 million for the quarter ended June 30, 2024 and; Recorded total net revenue from the sale of AGGRASTAT® of $1.7 million during the quarter ended June 30, 2025 compared to $1.8 million for the quarter ended June 30, 2024 and; Recorded total net revenue from the Marley Drug business of $3.1 million ($908,000 from sales of ZYPITAMAG®, and $2.2 million from other pharmacy revenue) during the quarter ended June 30, 2025 compared to $2.7 million ($790,000 from sales of ZYPITAMAG®and $1.9 million from other pharmacy revenue) for the quarter ended June 30, 2024 and; Recorded total net revenue from the sale of ZYPITAMAG® of $1.7 million ($751,000 through the insured business, and $908,000 through Marley Drug) during the quarter ended June 30, 2025 compared to $1.4 million ($654,000 through insured business and $790,000 through Marley Drug) for the quarter ended June 30, 2024 and; Recorded total net revenue from the Gateway Pharmacy business of $764,000 during the quarter ended June 30, 2025 and; Recorded total net revenue from the West Olympia Pharmacy business of $328,000 during the quarter ended June 30, 2025 and; Medicure invested $741,000 in research and development during the quarter ended June 30, 2025, underscoring our commitment to advancing innovative therapies, such as the Phase 3 trial of Medicure's investigational product MC-1 for the treatment of PNPO deficiency and delivering long-term value to patients and shareholders, and; Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended June 30, 2025 was negative $28,000 compared to adjusted EBITDA of negative $514,000 for the quarter ended June 30, 2024 and; Net loss for the quarter ended June 30, 2025 was $786,000 or $0.08 per share compared to a net loss of $1.2 million or $0.12 per share for the quarter ended June 30, 2024. Financial Results AGGRASTAT® revenues have remained consistent when compared to the same period in the previous year, as described above, despite competition from generic tirofiban hydrochloride.